Cannabinoid physiology and pharmacology: 30 years of progress.

By Allyn C. Howlett, C. Breivogel, S. Childers, S. Deadwyler, R. Hampson, L. Porrino. Neuropharmacology, 2004

637 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The endocannabinoid system drives neural progenitor proliferation (2005, positive): “Keywords: cannabinoid • CB1 receptor • NP annabinoids and their endogenous counterparts, the endocannabinoids (eCBs), exert their actions in the brain through activation of the seven-transmembrane receptor CB1 (1, 2).”
Cannabinoid-based drugs as anti-inflammatory therapeutics (2005, methodology): “For example, the CB 1 antagonist SR141716A has been shown to effectively promote weight loss and smoking cessation in preclinical and clinical trial”
Is there a common molecular pathway for addiction? (2005, background): “Each drug activates dopaminergic transmission in the NAc and many produce dopamine-like, yet dopamine-independent effects on the same NAc neurons, in many cases via indirect, circuit-level action”
The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…marijuana and the recent resurgence of interest in its medicinal properties have been the subject of excellent reviews (Mechoulam, 1986; Iversen, 2000; Di Marzo et al., 2004; Howlett et al., 2004; Pertwee, 2005a; Piomelli, 2005; Di Marzo and Petrocellis, 2006; Mackie, 2006; Pagotto et al., 2006).”